Inhibition of vascular endothelial growth factor (VEGF) signaling (either via neutralization via antibodies or indirectly via tyrosine kinase inhibition), commonly used in the treatment of various malignancies, has also been associated with increased risk of myocardial infarction [16]. This evidence concerns the gene VEGFA and myocardial infarction.